Jagsonpal spreads its wings
By Our Corporate Bureau | 10 Jul 2004
Jagsonpal Pharmaceuticals has announced that the next step in its business strategy is to exploit the increased presence and demand for domestically produced drugs in foreign markets.
A study of the current levels and future trends of exports to various parts of the world and subsequent SWOT analysis by a dedicated team, has pinpointed the Asian markets as the primary focus area.
The registration process for a wide range of its specialty products, in the segments of progestogens, antioxidants, injectible anaesthetic agents, anabolics and haematinics is on the verge of completion in Belarus.
Says Rajpal Singh Kochhar, MD, Jagsonpal, "The company expects to export formulations worth $4 million in the current fiscal to Belarus, Sri Lanka and Vietnam, etc".
A European company has entered into an agreement with Jagsonpal for exclusive access to technology and material pertaining to dextropropoxyphene, for which the latter is the second biggest manufacturer in the country.
In addition, companies from several countries, including Switzerland, Germany and Korea are exploring the possibility of accessing selling rights and technological expertise for general anaesthetic agents from Jagsonpal.
